Clinical Trial Update: A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating long-term safety, tolerability, and efficacy of Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Status: COMPLETED | Results posted: 2022-11-03